JP MORGAN/CALL/BECTON DICKINSON AND CO./315/0.1/17.01.25 Stock

Warrant

DE000JL7YWA4

Real-time Bid/Ask 13:03:33 2024-05-21 EDT
0.21 EUR / 0.3 EUR +10.87% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./315/0.1/17.01.25
1 month-23.33%
3 months-65.67%
Date Price Change
24-05-21 0.22 -4.35%
24-05-20 0.23 +4.55%
24-05-17 0.22 -15.38%
24-05-16 0.26 +8.33%
24-05-15 0.24 -7.69%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 03:31 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL7YWA
ISINDE000JL7YWA4
Date issued 2023-07-26
Strike 315 $
Maturity 2025-01-17 (241 Days)
Parity 10 : 1
Emission price 1.7
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.72
Lowest since issue 0.22
Spread 0.09
Spread %30.00%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW